T. Ozdoganoglu and M. Songu, The burden of allergic rhinitis and asthma, Therapeutic Advances in Respiratory Disease, vol.6, issue.1, pp.11-23, 2012.
DOI : 10.1177/1753465811431975

J. Bousquet, N. Khaltaev, and A. Cruz, Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*, Allergy, vol.5, issue.Suppl. 4, pp.8-160, 2008.
DOI : 10.1111/j.1398-9995.2007.01620.x
URL : https://hal.archives-ouvertes.fr/inserm-00815533

D. Sur and S. Scandale, Treatment of allergic rhinitis, Am Fam Physician, vol.81, pp.1440-1446, 2010.

D. Wallace, M. Dykewicz, and D. Bernstein, The diagnosis and management of rhinitis: An updated practice parameter, Journal of Allergy and Clinical Immunology, vol.122, issue.2, pp.1-84, 2008.
DOI : 10.1016/j.jaci.2008.06.003

P. Devillier, J. Dreyfus, P. Demoly, and M. Calderon, A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis, BMC Medicine, vol.129, issue.1, p.71, 2014.
DOI : 10.1016/j.jaci.2011.12.973
URL : https://hal.archives-ouvertes.fr/inserm-00990904

. Demoly, Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose, Clinical and Translational Allergy, vol.35, issue.160???166, p.44, 2015.
DOI : 10.1186/s13601-015-0088-1
URL : https://hal.archives-ouvertes.fr/inserm-01254140

M. Focke, I. Swoboda, K. Marth, and R. Valenta, Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity, Clinical & Experimental Allergy, vol.40, issue.3, pp.385-97, 2010.
DOI : 10.1111/j.1365-2222.2009.03443.x

C. Incorvaia, Preventive capacity of allergen immunotherapy on the natural history of allergy, J Prev Med Hyg, vol.54, pp.71-75, 2013.

S. Lin, N. Erekosima, and C. Suarez-cuervo, Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma: Comparative Effectiveness Review, Rockville: Rockville (MD, 2013.

M. Calderon, F. Simons, and H. Malling, Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile, Allergy, vol.156, issue.Suppl 1, pp.302-313, 2012.
DOI : 10.1111/j.1398-9995.2011.02761.x

G. Canonica, L. Cox, and R. Pawankar, Sublingual immunotherapy: World Allergy Organization position paper 2013 update, World Allergy Organization Journal, vol.7, issue.1, 2014.
DOI : 10.1186/2045-7022-2-20

P. Demoly and M. Calderon, Dosing and efficacy in specific immunotherapy, Allergy, vol.120, issue.63 Suppl, pp.38-40, 2011.
DOI : 10.1111/j.1398-9995.2011.02631.x

A. Meadows, B. Kaambwa, and N. Novielli, A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis, Health Technol Assess, vol.17, issue.27, pp.1-322, 2013.
DOI : 10.3310/hta17270

P. Demoly, M. Calderon, and T. Casale, ???The value of pre- and co-seasonal sublingual immunotherapy in pollen-induced allergic rhinoconjunctivitis???, Clinical and Translational Allergy, vol.20, issue.Suppl 97, p.18, 2015.
DOI : 10.1186/s13601-015-0061-z

M. Calderon, D. Larenas, and J. Kleine-tebbe, European Academy of Allergy and Clinical Immunology task force report on ???dose-response relationship in allergen-specific immunotherapy???, Allergy, vol.1, issue.Pt 1, pp.1345-59, 2011.
DOI : 10.1111/j.1398-9995.2011.02669.x

K. Bergmann, P. Demoly, and M. Worm, Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis, Journal of Allergy and Clinical Immunology, vol.133, issue.6, pp.1608-1614, 2014.
DOI : 10.1016/j.jaci.2013.11.012

A. Didier, H. Malling, and M. Worm, Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5???grass pollen tablet for seasonal allergic rhinitis, Journal of Allergy and Clinical Immunology, vol.120, issue.6, pp.1338-1383, 2007.
DOI : 10.1016/j.jaci.2007.07.046

H. Ott, J. Sieber, and R. Brehler, Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study, Allergy, vol.34, issue.Suppl. 81, pp.1394-401, 2009.
DOI : 10.1111/j.1398-9995.2009.02194.x

L. Wang, J. Yin, and R. Fadel, House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma, Allergy, vol.131, issue.Suppl. 91, pp.1181-1189, 2014.
DOI : 10.1111/all.12188

M. Worm, S. Rak, and F. De-blay, Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study, Clinical and Translational Allergy, vol.4, issue.1, p.7, 2014.
DOI : 10.1016/j.jaci.2011.12.973

D. Larenas-linnemann and L. Cox, European allergen extract units and potency: review of available information, Annals of Allergy, Asthma & Immunology, vol.100, issue.2, pp.137-182, 2008.
DOI : 10.1016/S1081-1206(10)60422-X

F. Frati, S. Scurati, and P. Puccinelli, Development of an allergen extract for sublingual immunotherapy ??? evaluation of Staloral, Expert Opinion on Biological Therapy, vol.37, issue.9, pp.1207-1222, 2009.
DOI : 10.1097/ACI.0b013e32831411e9

G. Pajno, L. Caminiti, and G. Crisafulli, Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: A randomized controlled study, Pediatric Allergy and Immunology, vol.126, issue.Suppl.14, pp.803-810, 2011.
DOI : 10.1111/j.1399-3038.2011.01196.x

I. Stelmach, I. Kaluzinska-parzyszek, and J. Jerzynska, Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children, Allergy, vol.21, issue.Suppl 82, pp.312-332, 2012.
DOI : 10.1111/j.1398-9995.2011.02758.x

T. Zuberbier, C. Bachert, and P. Bousquet, GA2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma, Allergy, vol.61, issue.Suppl. 82, pp.1525-1555, 2010.
DOI : 10.1111/j.1398-9995.2010.02474.x

S. A. Summary-of-product-characteristics-stallergènes, Oralair ® 100 IR & 300 IR sublingual tablets, 2013.

L. Archila, J. Delong, and E. Wambre, T-cells exhibit varying degrees of cross-reactivity, implications for allergen-specific immunotherapy, Clinical & Experimental Allergy, vol.13, issue.7, pp.986-98, 2014.
DOI : 10.1111/cea.12324

T. Zuberbier, G. Canonica, and B. Da-silva, Specific immunotherapy with allergens: an important tool in the treatment of the allergic diseases, JDDG: Journal der Deutschen Dermatologischen Gesellschaft, vol.6, issue.suppl 82, pp.879-85, 2012.
DOI : 10.1111/j.1610-0387.2012.08017.x

S. Bonini, Regulatory Aspects of Allergen-Specific Immunotherapy, World Allergy Organization Journal, vol.5, issue.10, pp.120-123, 2012.
DOI : 10.1097/WOX.0b013e318272484e

S. Kaul, S. May, D. Luttkopf, and S. Vieths, Regulatory environment for allergen-specific immunotherapy, Allergy, vol.96, issue.Suppl. 14, pp.753-64, 2011.
DOI : 10.1111/j.1398-9995.2011.02552.x

T. Larsen, L. Poulsen, and M. Melac, Safety and tolerability of grass pollen tablets in sublingual immunotherapy ??? a phase-1 study, Allergy, vol.39, issue.14, pp.1173-1179, 2006.
DOI : 10.1046/j.1398-9995.2003.00387.x

H. Malling, A. Montagut, and M. Melac, Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis, Clinical & Experimental Allergy, vol.39, issue.3, pp.387-93, 2009.
DOI : 10.1111/j.1365-2222.2008.03152.x

A. Didier, M. Melac, and A. Montagut, Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy, Allergy, vol.16, issue.Suppl 81, pp.166-71, 2009.
DOI : 10.1111/j.1398-9995.2008.01767.x

L. Cox, T. Casale, and A. Nayak, Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: The importance of allergen-specific serum IgE, Journal of Allergy and Clinical Immunology, vol.130, issue.6, pp.1327-1334, 2012.
DOI : 10.1016/j.jaci.2012.08.032

U. Wahn, A. Tabar, and P. Kuna, Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis, Journal of Allergy and Clinical Immunology, vol.123, issue.1, pp.160-166, 2009.
DOI : 10.1016/j.jaci.2008.10.009

A. Didier, H. Malling, and M. Worm, Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2??years after treatment cessation, as measured by a recommended daily combined score, Clinical and Translational Allergy, vol.10, issue.Suppl 86, p.12, 2015.
DOI : 10.1186/s13601-015-0057-8

F. Horak, P. Zieglmayer, and R. Zieglmayer, Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber, Journal of Allergy and Clinical Immunology, vol.124, issue.3, pp.471-478, 2009.
DOI : 10.1016/j.jaci.2009.06.006

J. Ferrés, J. Justicia, and M. García, Efficacy of high-dose sublingual immunotherapy in children allergic to house dust mites in real-life clinical practice, Allergologia et Immunopathologia, vol.39, issue.3, pp.122-129, 2011.
DOI : 10.1016/j.aller.2010.01.008

J. Sieber, M. Neis, and R. Brehler, Increasing long-term safety of seasonal grass pollen sublingual immunotherapy: the ECRIT study, Expert Opinion on Drug Safety, vol.16, issue.1, pp.7-13, 2012.
DOI : 10.1111/j.1365-2222.2005.02240.x

A. Didier and B. Bons, Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review, Expert Opinion on Drug Safety, vol.19, issue.1, pp.777-88, 2015.
DOI : 10.1097/ACI.0b013e3283588c8d

K. Lyseng-williamson, Standardized sublingual allergen extract solution (Staloral??): a guide to its use as allergen-specific immunotherapy, Drugs & Therapy Perspectives, vol.15, issue.7, pp.10-1007, 2014.
DOI : 10.1007/s40267-014-0165-x

P. Demoly, L. Gall, M. Roux, M. Zeldin, and R. , Safety and tolerability of high doses of sublingual tablet of house dust mite allergen extracts in subjects with house dust mite-associated respiratory allergy, Presented at: European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015

J. Seidenberg, G. Pajno, and C. Bauer, Safety and tolerability of seasonal ultra-rush, high-dose sublingual-swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observational study in 193 children and adolescents, J Investig Allergol Clin Immunol, vol.19, pp.125-156, 2009.

J. Corzo, A. Martínez-cañavate, and J. Ramos, Estudio de tolerabilidad pauta rápida con immunoterapia sublingual con Staloral 300 Rápid ® en niños, Presented at: XXXVI Congreso de la Sociedad Española de Inmunología Clínica y Alergología Pediátrica (SEICAP) 2012

F. Trebuchon, M. David, and P. Demoly, Medical Management and Sublingual Immunotherapy Practices in Patients with House Dust Mite-Induced Respiratory Allergy: A Retrospective, Observational Study, International Journal of Immunopathology and Pharmacology, vol.39, issue.1, pp.193-206, 2012.
DOI : 10.1016/j.jaci.2006.02.040

F. Trebuchon, M. Lheritier-barrand, M. David, and P. Demoly, Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens, Clinical and Translational Allergy, vol.4, issue.1, p.15, 2014.
DOI : 10.1016/j.jaip.2013.03.013

D. Antolin, T. Valbuena, and A. Valls, One season of treatment with 5 grass pollen tablets in adults demonstrated a reduction in disease symptoms and impacts. Findings of the SMILE study, Presented at: European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting 2013

. Demoly, Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose, Clinical and Translational Allergy, vol.35, issue.160???166, p.44, 2015.
DOI : 10.1186/s13601-015-0088-1
URL : https://hal.archives-ouvertes.fr/inserm-01254140

M. Fernandez-nieto, J. Alvarez, and M. Alvarado, What is the opinion of the patients under 5 grass pollen tablets immunotherapy? First season assessment in adults. Findings of the SMILE study, Presented at: European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting 2013

K. Lyseng-williamson, Sublingual five-grass pollen tablets (Oralair??): a guide to their use as allergen immunotherapy for grass pollen-induced allergic rhinoconjunctivitis, Drugs & Therapy Perspectives, vol.15, issue.5, pp.10-1007, 2014.
DOI : 10.1007/s40267-014-0131-7

G. Senna, C. Lombardi, G. Canonica, and G. Passalacqua, How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint, Journal of Allergy and Clinical Immunology, vol.126, issue.3, pp.668-677, 2010.
DOI : 10.1016/j.jaci.2010.06.045

F. Frati, L. Sensi, D. Rienzo, and V. , A model for management of sublingual immunotherapy, Eur Ann Allergy Clin Immunol, vol.35, pp.56-60, 2003.